Skip to content

Nuvation Bio

US · NUVB #2898 by market cap Listed 1970
3.80 -0.01 -0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 3.81 0.00%
After-hours 3.80 0.00%
Overnight 3.71 -2.62%
7.263.783.802026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NUVB?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -45.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 17.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 85.2% Better than 94%
Operating margin -338.7% Better than 5%
Net margin -325.3% Better than 4%
Return on equity -53.2% Better than 9%
Return on invested capital -50.8% Better than 6%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -45.2% Better than 7%
6-month return -19.5% Better than 27%
12-month return (ex latest month) -32.8% Better than 8%
Distance below 52-week high 61.0% Better than 10%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 7.0x Better than 90%
Debt to assets 9.6% Better than 70%
Interest coverage -14.0x Better than 12%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 258.7% Better than 96%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.76%
1M -20.34%
3M -44.36%
6M -15.74%
YTD -57.59%
1Y -45.79%
3Y +181.48%
5Y -58.01%

Key statistics

Price & volume

Prev close
3.81
Open
3.77
Day range
3.72 - 3.91
Avg price
3.80
Volume
6.85M
Turnover
26.02M
Amplitude
4.99%
52-week range
3.71 - 9.75

Valuation

P/E
-6.33
P/E (TTM)
-9.74
P/B
5.88
EPS
-0.60
Net profit
-211.81M
Net assets
228.05M

Share structure

Market cap
1.34B
Float cap
1.01B
Shares out
353.02M
Float shares
265.54M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 1% of range
3.71 9.75

61.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-18.35M net over the window

Short interest

Shares short
62.00M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Nuvation Bio (NUVB)?

Nuvation Bio last traded at 3.80. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Nuvation Bio's market cap?

About 1.34B.

What is the P/E ratio of Nuvation Bio?

The trailing twelve-month P/E is -9.74. The Valuation tab shows it against the stock's own five-year range.

Does Nuvation Bio pay a dividend?

Nuvation Bio does not currently pay a regular dividend.

Is Nuvation Bio a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 13.63, which implies 258.7% upside from the current price. This is not investment advice.

What is Nuvation Bio's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Nuvation Bio a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Nuvation Bio discussion 0 comments

Add a comment